Skip to main content
Novartis: Revolade promising in trial for immune thrombocytopenia
10/18/2017

Novartis' drug Revolade was associated with increases in platelet counts and reductions in bleeding in a long-term trial involving patients with chronic and persistent immune thrombocytopenia.

Full Story: